Lymphocyte markers and natural killer cell activity in fibromyalgia syndrome: Effects of low-dose, sublingual use of human interferon-α

Medicine and Dentistry

• Fibromyalgia 100%
• Syndrome 100%
• Blood 80%
• Leukocyte 60%
• Patient 60%
• Low Drug Dose 40%
• Group Therapy 40%
• Natural Killer Cell 40%
• Cell Activity 40%
• Human Interferon 40%
• Therapeutic Procedure 40%
• Neoplasm 20%
• Lymphocyte 20%
• In Vitro 20%
• Phenotype 20%
• Clinical Study 20%
• Chromium 20%
• Anodyne 20%
• Flow Cytometry 20%
• Target Cell 20%
• Interferon 20%
• Chronic Fatigue Syndrome 20%
• Blood Sampling 20%
• Hypnotic Sedative Agent 20%
• Immunophenotyping 20%
• Lymphocyte Surface Marker 20%
• CD25+ T Lymphocyte 20%
• Phlebotomy 20%
• Analysis 20%
• Laboratory 20%
• Volunteer 20%
• Medication 20%
• Inpatient 20%
• Placebo 20%

Immunology and Microbiology

• White Blood Cell 60%
• Natural Killer Cell 60%
• Human Interferon 40%
• Low Drug Dose 40%
• Lymphocyte 40%
• CD4 20%
• Phenotype 20%
• HLA-DR 20%
• Interferon Type I 20%
• Blood Sampling 20%
• Target Cell 20%
• Chronic Fatigue Syndrome 20%
• CD25+ T Lymphocyte 20%
• Lymphocyte Surface Marker 20%
• Flow 20%

Neuroscience

• Fibromyalgia 100%
• Human Interferon 40%
• In Vitro 20%
• Phenotype 20%
• Flow Cytometry 20%
• CD4 20%
• Interferon 20%
• HLA-DR 20%
• Chronic Fatigue Syndrome 20%
• Immunophenotyping 20%
• Placebo 20%